101 related articles for article (PubMed ID: 33596023)
1. Identification of HLA-A*0201-restricted CTL Epitopes for MLAA-34-specific Immunotherapy for Acute Monocytic Leukemia.
Bai J; Wang J; Yang Y; Wang F; He A; Zhang W
J Immunother; 2021 May; 44(4):141-150. PubMed ID: 33596023
[TBL] [Abstract][Full Text] [Related]
2. Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.
Hundemer M; Schmidt S; Condomines M; Lupu A; Hose D; Moos M; Cremer F; Kleist C; Terness P; Belle S; Ho AD; Goldschmidt H; Klein B; Christensen O
Exp Hematol; 2006 Apr; 34(4):486-96. PubMed ID: 16569595
[TBL] [Abstract][Full Text] [Related]
3. HLA-A2-restricted cytotoxic T lymphocyte epitopes from human heparanase as novel targets for broad-spectrum tumor immunotherapy.
Chen T; Tang XD; Wan Y; Chen L; Yu ST; Xiong Z; Fang DC; Liang GP; Yang SM
Neoplasia; 2008 Sep; 10(9):977-86. PubMed ID: 18714399
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of HLA-A*02-restricted Hantaan virus multiple-antigenic peptide for CD8
Ma Y; Tang K; Zhang Y; Zhang C; Zhang Y; Jin B; Ma Y
Virol J; 2020 Jan; 17(1):15. PubMed ID: 32005266
[TBL] [Abstract][Full Text] [Related]
5. Protective CD8
Ma Y; Tang K; Zhang Y; Zhang C; Cheng L; Zhang F; Zhuang R; Jin B; Zhang Y
Virol J; 2020 Oct; 17(1):146. PubMed ID: 33028368
[TBL] [Abstract][Full Text] [Related]
6. Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens.
Altvater B; Pscherer S; Landmeier S; Kailayangiri S; Savoldo B; Juergens H; Rossig C
Cancer Immunol Immunother; 2012 Mar; 61(3):385-96. PubMed ID: 21928126
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28.
Han JF; Zhao TT; Liu HL; Lin ZH; Wang HM; Ruan ZH; Zou LY; Wu YZ
Cancer Immunol Immunother; 2006 Dec; 55(12):1575-83. PubMed ID: 16534571
[TBL] [Abstract][Full Text] [Related]
8. Identification and functional characterization of the novel acute monocytic leukemia associated antigen MLAA-34.
Zhang PY; Zhang WG; He AL; Wang JL; Li WB
Cancer Immunol Immunother; 2009 Feb; 58(2):281-90. PubMed ID: 18592235
[TBL] [Abstract][Full Text] [Related]
9. The immunogenicity of a novel cytotoxic T lymphocyte epitope from tumor antigen PL2L60 could be enhanced by 4-chlorophenylalanine substitution at position 1.
Shi RR; Liu J; Zou Z; Qi YM; Zhai MX; Zhai WJ; Gao YF
Cancer Immunol Immunother; 2013 Nov; 62(11):1723-32. PubMed ID: 24077852
[TBL] [Abstract][Full Text] [Related]
10. Generation of human tumor-specific CTLs in HLA-A2.1-transgenic mice using unfractionated peptides from eluates of human primary breast and ovarian tumors.
Gritzapis AD; Sotiriadou NN; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2004 Nov; 53(11):1027-40. PubMed ID: 15164233
[TBL] [Abstract][Full Text] [Related]
11. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2).
Yoshimura S; Tsunoda T; Osawa R; Harada M; Watanabe T; Hikichi T; Katsuda M; Miyazawa M; Tani M; Iwahashi M; Takeda K; Katagiri T; Nakamura Y; Yamaue H
PLoS One; 2014; 9(1):e85267. PubMed ID: 24416375
[TBL] [Abstract][Full Text] [Related]
12. Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation.
Chakraborty NG; Stevens RL; Mehrotra S; Laska E; Taxel P; Sporn JR; Schauer P; Albertsen PC
Cancer Immunol Immunother; 2003 Aug; 52(8):497-505. PubMed ID: 12783216
[TBL] [Abstract][Full Text] [Related]
13. Identification of Novel Cytotoxic T Lymphocyte Epitopes of Drug- Resistance Related Protein InhA from Mycobacterium tuberculosis.
Li D; Dou Z; Wu Y; Qi Y; Chen J; Gao Y
Protein Pept Lett; 2020; 27(11):1141-1150. PubMed ID: 32370703
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel MAGE-A6- and MAGE-A12-derived HLA-A24-restricted cytotoxic T lymphocyte epitopes using an in silico peptide-docking assay.
Akiyama Y; Komiyama M; Nakamura Y; Iizuka A; Oshita C; Kume A; Nogami M; Miyata H; Ashizawa T; Yoshikawa S; Kiyohara Y; Yamaguchi K
Cancer Immunol Immunother; 2012 Dec; 61(12):2311-9. PubMed ID: 22707303
[TBL] [Abstract][Full Text] [Related]
15. A modified HLA-A*0201-restricted CTL epitope from human oncoprotein (hPEBP4) induces more efficient antitumor responses.
Sun W; Shi J; Wu J; Zhang J; Chen H; Li Y; Liu S; Wu Y; Tian Z; Cao X; Li N
Cell Mol Immunol; 2018 Aug; 15(8):768-781. PubMed ID: 29375131
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxic T lymphocyte epitopes from human heparanase can elicit a potent anti-tumor immune response in mice.
Tang XD; Liang GP; Li C; Wan Y; Chen T; Chen L; Yu ST; Xiong Z; Fang DC; Wang GZ; Yang SM
Cancer Immunol Immunother; 2010 Jul; 59(7):1041-7. PubMed ID: 20182872
[TBL] [Abstract][Full Text] [Related]
17. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
Lu C; Meng S; Jin Y; Zhang W; Li Z; Wang F; Wang-Johanning F; Wei Y; Liu H; Tu H; Su D; He A; Cao X; Zhou F
Br J Haematol; 2017 Aug; 178(3):413-426. PubMed ID: 28508448
[TBL] [Abstract][Full Text] [Related]
18. The cytotoxic T cell response to peptide analogs of the HLA-A*0201-restricted MUC1 signal sequence epitope, M1.2.
Mitchell MS; Lund TA; Sewell AK; Marincola FM; Paul E; Schroder K; Wilson DB; Kan-Mitchell J
Cancer Immunol Immunother; 2007 Mar; 56(3):287-301. PubMed ID: 16874487
[TBL] [Abstract][Full Text] [Related]
19. Identification of a novel HLA-A2-restricted mutated Survivin epitope and induction of specific anti-HCC CTLs that could effectively cross-recognize wild-type Survivin antigen.
Shen H; Shao HW; Chen XH; Wu FL; Wang H; Huang ZL; Shen J; Wang T; Zhang WF; Huang SL
Cancer Immunol Immunother; 2013 Feb; 62(2):393-403. PubMed ID: 22926105
[TBL] [Abstract][Full Text] [Related]
20. Substitution analog peptide derived from HER-2 can efficiently induce HER-2-specific, HLA-A24 restricted CTLs.
Mimura K; Kono K; Southwood S; Fikes J; Takahashi A; Miyagawa N; Sugai H; Fujii H
Cancer Immunol Immunother; 2006 Nov; 55(11):1358-66. PubMed ID: 16435129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
